To ask the Secretary of State for Health and Social Care, how many highly specialised technology evaluations of medicines for very rare diseases conducted by the National Institute for Health and Care Excellence resulted in (a) a positive recommendation, (b) an optimised recommendation, (c) a recommendation for managed access, (d) a negative recommendation and (e) termination in each financial year since 2018-19.
Answered on
20 October 2023
The following table shows a breakdown of technologies appraised through the National Institute for Health and Care Excellence’s highly specialised technology process by financial year from 2018/19:
Financial Year | 2018/19 | 2019/20 | 2020/21 | 2021/22 | 2022/23 | Total |
Recommended | 1 | 4 | 2 | 4 | 4 | 15 |
Optimised | 0 | 0 | 0 | 0 | 1 | 1 |
Not recommended | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 4 | 2 | 4 | 5 | 16 |
Terminated | 0 | 0 | 0 | 0 | 0 | 0 |